Inclusion Criteria:
* Phase 1: Dose Escalation Phase
1. High risk AML, including any of the following:
1. Relapsed or refractory disease
2. TP53 mutant AML
3. Adverse risk cytogenetics including any of the following: 3 or more abnormalities; deletions involving chromosomes 5, 7, or 17; abnormalities in chromosome 11 involving MLL; t(6;9); inv(3) or t(3;3)
2. ECOG performance status 0-2
3. Age 18 years or older
4. Adequate organ function as defined by all of the following:
1. Creatinine clearance ≥30 mL/min, determined by the Cockroft-Gault formula, or measured by a 24 hour urine collection
2. AST and ALT ≤3 x ULN and bilirubin ≤1.5 x ULN (unless considered due to Gilbert's syndrome or of non-hepatic origin i.e. leukemic involvement).
5. Patients must be at least 2 weeks from major surgery, radiation therapy, or participation in other investigational trials, and must have recovered from clinically significant toxicities related to these prior treatments.
6. Patients must voluntarily sign and date an informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the i initiation of any screening or study specific procedures.
7. Female patients of childbearing potential must have negative results for a pregnancy test
8. Patients must be willing to use appropriate contraception
* Phase 2: Dose Expansion Phase During the Phase 2 portion of the study, the subject population will be limited to patients with previously untreated AML with a mutation in TP53. All other inclusion criteria described above will apply.
Exclusion Criteria:
\- Key exclusion criteria (apply to both Phase 1 and Phase 2 portions of the study):
1. Concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in this protocol
2. Patients suitable for and willing to receive intensive induction chemotherapy
3. Use of investigational agents and/or anticancer therapy within 2 weeks of study entry (with the exception of hydroxyurea, which is permitted before and during Cycle 1 of therapy until D10, at the discretion of the investigator)
4. Prior treatment with venetoclax, decitabine, or azacitidine
5. Diagnosis of acute promyelocytic leukemia
6. Pregnant or breastfeeding patients
7. Patient known to be positive for HIV
8. Known CNS involvement with AML
9. Evidence of other clinically significant uncontrolled condition(s) including, but not limited to:
1. Uncontrolled and/or active systemic infection (viral, bacterial or fungal)
2. Chronic hepatitis B virus (HBV) or hepatitis C (HCV) requiring treatment. Note: subjects with serologic evidence of prior vaccination to HBV (i.e. hepatitis B surface (HBs) antigen negative-, anti-HBs antibody positive and anti-hepatitis B core (HBc) antibody negative) or positive anti-HBc antibody from intravenous immunoglobulins (IVIG) may participate.
3. An active second cancer that requires treatment within 6 months of study entry
10. Cardiac history including the following:
1. History of CHF requiring treatment or Ejection Fraction ≤ 50%
2. Subject has a cardiovascular disability status of New York Heart Association
Class \> 2, defined as:
i. Cardiac disease in which patients are comfortable at rest but ordinary physical activity ii. Results in fatigue, palpitations, dyspnea, or anginal pain c. Chronic stable angina
11. Treatment with any of the following within 7 days prior to the first dose of study drug:
1. Steroid therapy for anti-neoplastic intent
2. Moderate or strong cytochrome P450 3A (CYP3A) inducers
12. Administration or consumption of any of the following within 3 days prior to the first dose of study drug:
1. Grapefruit or grapefruit products
2. Seville oranges (including marmalade containing Seville oranges)
3. Star fruit
